Clinical Trial Detail

NCT ID NCT03435640
Title A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Nektar Therapeutics
Indications

melanoma

colorectal cancer

ovarian carcinoma

renal cell carcinoma

triple-receptor negative breast cancer

Merkel cell carcinoma

transitional cell carcinoma

sarcoma

Therapies

NKTR-214 + NKTR-262

Nivolumab + NKTR-214 + NKTR-262

Age Groups: adult senior

No variant requirements are available.